[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,500
  • Shares Outstanding, K 82,273
  • Annual Sales, $ 70 K
  • Annual Income, $ -84,950 K
  • EBIT $ -84 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.49
  • Price/Sales 1,392.31
  • Price/Cash Flow N/A
  • Price/Book 12.59

Options Overview Details

View History
  • Implied Volatility 115.15% (-39.05%)
  • Historical Volatility 70.78%
  • IV Percentile 5%
  • IV Rank 5.60%
  • IV High 908.26% on 08/07/25
  • IV Low 68.09% on 01/28/26
  • Expected Move (DTE 3) 0.1020 (9.27%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 297
  • Volume Avg (30-Day) 2,379
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 80,783
  • Open Int (30-Day) 76,378
  • Expected Range 0.9980 to 1.2020

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 3
  • High Estimate $-0.23
  • Low Estimate $-0.34
  • Prior Year $-0.61
  • Growth Rate Est. (year over year) +54.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +3.77%
on 06/11/26
1.4500 -24.14%
on 05/22/26
-0.3100 (-21.99%)
since 05/12/26
3-Month
1.0300 +6.80%
on 04/10/26
1.7900 -38.55%
on 05/08/26
-0.5800 (-34.52%)
since 03/12/26
52-Week
1.0300 +6.80%
on 04/10/26
2.9789 -63.07%
on 09/09/25
-0.9800 (-47.12%)
since 06/12/25

Most Recent Stories

More News
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK , June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ:...

INO : 1.1000 (unch)
INOVIO to Participate in Upcoming Scientific and Investor Conferences

PLYMOUTH MEETING, Pa. , May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 1.1000 (unch)
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young...

INO : 1.1000 (unch)
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

PLYMOUTH MEETING, Pa. , May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 1.1000 (unch)
Inovio: Q1 Earnings Snapshot

Inovio: Q1 Earnings Snapshot

INO : 1.1000 (unch)
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

PLYMOUTH MEETING, Pa. , May 13, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 1.1000 (unch)
INOVIO to Participate in Upcoming Scientific Conferences

PLYMOUTH MEETING, Pa. , May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 1.1000 (unch)
INOVIO to Report First Quarter Financial Results on May 13, 2026

PLYMOUTH MEETING, Pa. , May 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 1.1000 (unch)
Inovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December...

INO : 1.1000 (unch)
INO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses in Inovio to Contact Him Directly to Discuss Their Options...

INO : 1.1000 (unch)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 1.1833
2nd Resistance Point 1.1667
1st Resistance Point 1.1333
Last Price 1.1000
1st Support Level 1.0833
2nd Support Level 1.0667
3rd Support Level 1.0333

See More

52-Week High 2.9789
Fibonacci 61.8% 2.2344
Fibonacci 50% 2.0044
Fibonacci 38.2% 1.7745
Last Price 1.1000
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.